Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Enliven Therapeutics, with a price target of $62.00. Accor...

Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Partners (MOLN), Enliven Therapeutics (ELV...

Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enliven Therapeutics (ELVN), Molina Healthcare (MO...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$34.30	-1.18%	221.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$34.30	-1.2%	221.17K
3
4
5
6

ELVN

ELVN

Dividend Overview

Get Enliven Therapeutics Inc. Data in Excel

Get Enliven Therapeutics Inc. Data in Excel